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Abstract 
Purpose: With growing evidence that rare single gene disorders present in the neonatal period, there is a need for 
rapid, systematic, and comprehensive genomic diagnoses in ICUs to assist acute and long‑term clinical decisions. This 
study aimed to identify genetic conditions in neonatal (NICU) and paediatric (PICU) intensive care populations.
Methods: We performed trio whole genome sequence (WGS) analysis on a prospective cohort of families recruited 
in NICU and PICU at a single site in the UK. We developed a research pipeline in collaboration with the National Health 
Service to deliver validated pertinent pathogenic findings within 2–3 weeks of recruitment.
Results: A total of 195 families had whole genome analysis performed (567 samples) and 21% received a molecular 
diagnosis for the underlying genetic condition in the child. The phenotypic description of the child was a poor pre‑
dictor of the gene identified in 90% of cases, arguing for gene agnostic testing in NICU/PICU. The diagnosis affected 
clinical management in more than 65% of cases (83% in neonates) including modification of treatments and care 
pathways and/or informing palliative care decisions. A 2–3 week turnaround was sufficient to impact most clinical 
decision‑making.
Conclusions: The use of WGS in intensively ill children is acceptable and trio analysis facilitates diagnoses. A gene 
agnostic approach was effective in identifying an underlying genetic condition, with phenotypes and symptomatol‑
ogy being primarily used for data interpretation rather than gene selection. WGS analysis has the potential to be a 
first‑line diagnostic tool for a subset of intensively ill children.
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Introduction
Given the life-threatening circumstances of children 
entering intensive care, effective management relies on 
comprehensive monitoring, data acquisition and rapid 
clinical responses. In 2016 in the UK, there were 636,401 
deliveries in National Health Service (NHS) hospitals and 
95,000 babies (15%) were admitted to neonatal inten-
sive care post-delivery, remaining there for 4–93  days 
depending on gestational age [1, 2]. With growing evi-
dence that rare diseases (defined as < 1 in 2000 indi-
viduals) are collectively relatively common (6% of the 
population) and that rare genetic variants underlie many 
congenital presentations, whole exome and genome 
sequencing is increasingly being used in this clinical set-
ting [3–9].
Studies have shown that early molecular diagnoses 
improve outcomes and reduce healthcare costs [10–12]. 
Provisioning of a rapid but affordable genomic testing 
strategy within a national healthcare service in order 
to deliver equity of access is nevertheless challenging 
[13]. As with all intensive care procedures, balancing 
the extreme stress of families with the complexities of 
an informed consent requires skill and sensitivity while 
incomplete understanding of new technology creates 
uncertainty for care providers [14]. Lack of consensus 
on reporting uncertainty and additional findings [15, 16] 
requires careful consideration of genome-wide sequence 
analysis in the intensive care setting.
The objectives of this study were (1) to establish a 
whole genome sequencing (WGS) analysis pipeline in 
the intensive care context and deliver clinically relevant 
results in a timely manner, (2) determine the prevalence 
of underlying genetic conditions in NICU and PICU 
populations and whether diagnosis influences clinical 
management, (3) to investigate the correlation of clinical 
features and genotype in very young children and (4) to 
create a recallable resource of children with rare disease 
for long-term follow-up and research.
Methods
Recruitment and consent
Participants for this study were recruited through NHS 
Cambridge University Hospitals Foundation Trust under 
Cambridge South Research Ethics Committee approval 
13/EE/0325. The neonatal and paediatric intensive care 
units have 40 and 13 beds respectively and have on aver-
age 896 and 639 admissions per year. The recruitment 
criteria were broad and inclusive for any cases with a 
possible single gene disorder (Supp. Table  1). In NICU, 
exclusion criteria were children admitted for short 
stay post-delivery surveillance, prematurity without 
additional features, babies with a clear antenatal or deliv-
ery history suggestive of a non-genetic cause and those 
babies where a genetic diagnosis was already made. 
Babies with congenital anomalies, neurological symptom 
including seizures, suspected metabolic disease, surgical 
necrotizing enterocolitis, extreme intrauterine growth 
retardation and unexplained critical illness of likely 
genetic etiology were all eligible for the study. In PICU, 
inclusion criteria were the same as for NICU but cases of 
clear trauma, malignancy and bronchiolitis or respiratory 
tract infections in an otherwise well child were ineligible.
For all consented children, the detailed clinical history 
and clinical features were extracted from the electronic 
medical records. These were converted into standardized 
terms for comparison using a human phenotype ontology 
term (HPO [17]) and a pedigree was completed with the 
parents at the time of consenting.
Whole genome sequence analysis
A minimum of 500  µL of fresh blood in EDTA was 
requested to yield a minimum of 1 µg of DNA for WGS. 
Extracted DNA samples were shipped to an external 
WGS sequencing facility (Illumina, UK). WGS (30–40× 
coverage for the nuclear genome and 800–1000× for 
the mitochondrial genome), quality control, read align-
ment to the human reference genome build 37, and 
variant calling were performed by Illumina as described 
[18]. Genome data has been deposited at the European 
Genome-phenome Archive (EGA) under accession num-
ber EGAD00001004357. Variant annotation and filtering 
were performed in house (see Supplementary Methods) 
[19–22]. No gene list was used if both parents were avail-
able but a filter for 3809 genes with potential early-onset 
presentation was used for singletons.
Multidisciplinary team assessment, clinical reporting 
and counselling
Consistent with NHS clinical genetics pathways, candi-
date variants were reviewed at a multidisciplinary team 
meeting (MDT), which included research bioinformatics 
analysts, clinical scientists, clinical geneticists, neonatal 
and paediatric intensivists, and neurologists as required. 
Additional genetic findings not related to the presenting 
complaint [16] were not assessed or reported as per the 
Take‑home message 
Children in intensive care frequently have a rare underlying genetic 
condition. Rapid genetic testing reveals a diagnosis in ~20% of case, 
but the clinical presentation is often atypical. Greater than 65% of 
diagnoses resulted in modification of treatments or care pathways 
and a 2–3 week diagnostic pipeline was sufficient to impact most 
clinical decision making.
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consent and genetic variants of uncertain significance 
(VUS) were not reported; however, VUS were curated for 
research and re-analysis. Pathogenic/likely pathogenic 
variants were confirmed by Sanger sequence analysis and 
a clinical report was issued according to the American 
College of Medical Genetics (ACMG) variant classifica-
tion scheme. Results were communicated to the family 
by a geneticist or appropriate specialist and intensivists 
referred families to Clinical Genetics for further evalua-
tion of all abnormal results.
Phenotypic comparison analysis
Pairwise similarity scores between clinical features 
using HPO term profiles (either proband-proband or 
proband-gene) were calculated using the R analysis pack-
age ontologyX and HPO release 2018-10-09 [17, 23]. 
The proband-proband scores were used to hierarchically 
cluster and categorise probands into phenotypic groups. 
Enrichment analysis of HPO terms was performed with 
Fisher’s exact test, FDR < 0.1. See Supplementary Meth-
ods for details.
Results
Recruitment of cohort
A total of 414 families were approached and offered WGS 
analysis between the period of December 2016 and Sep-
tember 2018 (Fig.  1), 380 were families with a child in 
the NICU or PICU and the rest were referred from other 
departments. In NICU, 113 families consented to join the 
study (47% of eligible cases, ~ 10% of all babies in the unit 
over the recruitment period). In PICU, 66 families con-
sented to join the study (48% of eligible cases, ~ 8% of all 
children in the unit). Of the recruited families, 13 were 
not sequenced or were pending (see Fig. 1).
Recruitment criteria were broad and inclusive for any 
case with a possible undiagnosed single gene disorder 
(Supp. Table 1). In total, 208 families were recruited (50% 
of total eligible cases) and 69 families actively declined to 
take part (17%). The remainder were either lost to follow-
up or remained undecided about participation by the 
time of discharge or repatriation to a more local hospital.
Of the 195 probands and their families that were ana-
lysed (567 genomes total), both parents were included 
in 90% of cases (Table 1). Most were recruited from the 
NICU (54%) and PICU (31%) (Table  1, Supp. Table  2). 
Twenty-eight probands (15%) were referred from 
Fig. 1 Recruitment summary of cohort. Families were recruited from the neonatal intensive care unit (NICU), paediatric intensive care unit (PICU) 
and paediatric neurology or clinical genetics department (N/G)
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paediatric neurology or clinical genetics. In the NICU, 
the ages of the probands at consent ranged from 1  day 
postnatal to 6  months old and the median age was 
12 days postnatal (equivalent to a median corrected ges-
tational age of + 4 days because 50% of the neonates were 
premature) (Supp. Fig. 1). For the others, the age at con-
sent ranged from 8 days to 16 years (median 24 months, 
plus an outlier of 23  years). Only 50% of the probands 
had routine comparative genomic hybridization (aCGH) 
microarray testing, which is the first-line test for children 
with multiple congenital abnormalities. Overall, recruit-
ment rates were much higher than expected given that 
blood samples were requested from both parents.
Rapid diagnoses
Forty cases received a diagnosis via WGS analysis (21% 
diagnostic rate), which either fully (95%) or partially 
(5%) explained the phenotype. The time from recruit-
ment to preliminary findings reduced over the course 
of the project and reached steady state at about 3 weeks 
(Supp. Fig.  2). From January 2018 onwards, the median 
time from recruitment to accredited report was less than 
5 weeks with the fastest turnaround being 21 days. Much 
of the variability stemmed from difficulty in collect-
ing parental samples in a timely manner (Supp. Fig. 3a). 
Sequencing and analysis took a median of 16 days (Supp. 
Fig.  3b–d) while MDT meetings, confirmation, and 
clinical reporting took 11 days (Supp. Fig. 3e–f). Iterative 
redesign of processes allowed continuous improvement 
of the pipeline as shown by the reduced median turna-
round time to diagnosis over the recruitment period. 
Two diagnoses were made after subsequent re-analysis as 
these disease-causing genes were newly reported in the 
literature.
The diagnostic rate in the NICU was 13% and in the 
PICU it was 25%. The referrals from the paediatric neu-
rology and/or clinical genetics departments had a 39% 
diagnostic rate (Supp. Table  3). Two-thirds of the diag-
noses were de novo variants; familial X-linked, com-
pound heterozygous and homozygous variants were also 
observed (Table  1). Parental sequence data were crucial 
for calling pathogenic bi-allelic compound heterozygous 
variants in trans. Thus, accelerated WGS testing is feasi-
ble in an NHS-compliant genetics pipeline with an over-
all diagnostic yield of 21%.
Impact on clinical care
The 40 diagnoses reported included pathogenic or likely 
pathogenic variants in a broad range of rare disorders 
including encephalopathies, myopathies, skeletal dyspla-
sia, and various syndromes (Supp. Tables  4 and 5). The 
age at recruitment for the diagnosed probands ranged 
from 1 day to 15 years. The most common clinical impact 
of the diagnoses was to improve ongoing management by 
Table 1 Summary of  recruitment demographics, family structure, and  types of  mutation reported including  mode 
of inheritance
a Includes trio + sibling (4) and trio + grandparents (1)
b Includes two cases from other postnatal wards
c In addition there is one 23-year-old
d One case (44) was a duo and likely pathogenic pending confirmation of de novo; one case (138) was a missense VUS in trans with a pathogenic loss of function 
variant
Number of probands sequenced 195
Family structure Singleton: 3 (1%), Parent + child: 18 (9%), Trio: 169 
(87%),  Othera: 5 (3%)
Gender Male: 99 (51%), Female: 96 (49%)
Recruitment ward NICUb: 106 (54%), PICU: 61 (31%),
Paediatric Neurology: 23 (12%), Clinical Genetics: 5 (3%)
Age at recruitment NICU: 1 day–6 months (median 12 days)
Other: 8 days–16.8  yearsc (median 24 months)
Genetic diagnosis via WGS 40 (21%)
ACMG classification Pathogenic: 21, Likely pathogenic: 17,  VUSd: 2
Contribution to phenotype Fully explained: 38, Partially explained: 2
Inheritance pattern De novo: 27 (autosomal dominant: 24, X‑linked domi‑
nant: 2, X‑linked recessive: 1)
Inherited: 13 (homozygous: 4, compound heterozy‑
gous: 6, X‑linked recessive: 2, X‑linked dominant: 1)
Variant type Loss of function: 18 (frameshift: 8, stop gain: 3, splicing: 
4, structural variant: 3), missense: 21, in‑frame dele‑
tion: 1
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informing established specialist care pathways for older 
children (35%) or initiating new specialist care path-
ways (48%), especially for neonates and infants (Fig.  2). 
In a few cases (13%), the diagnosis affected acute clini-
cal management decisions and modified treatment: 
change in epilepsy medication due to an SCN1A muta-
tion, Dravet syndrome; prophylactic antibiotic use for a 
primary ciliary dyskinesia (DNAH11); and consideration 
of a ketogenic diet for children with pyruvate dehydro-
genase deficiency (PDHA1), Dravet syndrome (SCN1A), 
and severe West syndrome with a CDKL5 mutation.
To date, for at least seven cases, distinguishing between 
inherited and de novo variants informed subsequent 
reproductive decisions. For 14 cases, the pathogenic 
variant(s) were inherited, conferring a significant recur-
rence risk for subsequent pregnancies. For example, in 
the case of family 114, the proband died from a novel 
mitochondrial disorder [24] due to inherited compound 
heterozygous variants in a mitochondrial complex I defi-
ciency gene, NDUFA6 and prenatal testing was offered in 
a subsequent pregnancy (Fig. 2).
In four cases of perinatal death, WGS provided a valu-
able etiological explanation. For family 101, the diag-
nosis of congenital titinopathy [25] was made in the 
second affected neonate. In four neonatal/infant cases, 
the molecular diagnosis informed discussion with the 
family about palliative care. Three older children were 
diagnosed with neurodegenerative conditions due to 
mutations in GFAP (Alexander disease), ALS2 (juve-
nile amyotrophic lateral sclerosis) and UBTF, a recently 
described syndrome of neurodegeneration and brain 
atrophy (families 127, 139 and 147). For these families, 
supportive care and the resolution of diagnostic uncer-
tainty was achieved but also brought painful realiza-
tion of severe and currently incurable conditions being 
diagnosed. These findings indicate a variety of ways that 
WGS impacts clinical management of intensively ill chil-
dren and their families.
Phenotype as predictor of genotype in young children
All probands were extensively phenotyped using 
Human Phenotype Ontology (HPO) terms extracted 
from the electronic health record. Analysis excluded 
maternal phenotypes and those relating to birth. The 
median number of non-redundant HPO terms per 
proband was 11, with 90% having at least five terms 
(Supp. Fig.  4). For most probands, the phenotypes fell 
into more than one major subclass of the root HPO 
term ‘Phenotypic abnormality’ and 80% have pheno-
types from at least five subclasses. The most common 
phenotypes were abnormalities of the nervous (70% of 
probands), respiratory (68%), digestive (67%), and car-
diovascular (61%) systems (Supp. Fig. 5).
In order to investigate the phenotypic composition of 
our cohort and to test the predictive value of specific 
phenotypes, we clustered the probands by phenotypic 
profile similarity and determined which phenotypes 
were enriched in each subgroup (see Supplementary 
Methods for details).
Clustering of the 106 patients recruited from the NICU 
(Supp. Fig. 6) revealed a few small groups with substan-
tially increased diagnostic rates (> 30% compared to 13% 
for the NICU cohort overall). The cases with dysmor-
phic phenotypes such as hypertelorism, cleft palate, and 
micrognathia and those with abnormal renal function 
had the highest diagnostic yield (groups 1–4, Table  2, 
Supp. Table  6). Cases with congenital heart disease, 
decreased body weight or sepsis were the next most likely 
cases to have a diagnosis (groups 5–10). The groups with 
no diagnoses to date (groups 11–15) were enriched for 
Fig. 2 Impact of diagnosis on each case. Cases are ordered by increasing age. Green, specialist care. Blue, modification of treatment. Yellow, recur‑
rence risk. Red, deceased and/or lethal condition. EIEE early infantile epileptic encephalopathy, Mito. mitochondrial, EI early infantile, NDD neurode‑
velopmental disorder, ND neurodegeneration
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suspected hypoxic ischaemic encephalopathy (HIE) and 
those with a general physiological disturbance.
In the 61 PICU cases, the phenotypic groups with the 
highest diagnostic rate were children with lactic acidosis 
and those with cerebral palsy and/or epilepsy (group1–3) 
(Table 2, Supp. Table 7, Supp. Fig. 7). Children with a dis-
tinct skeletal dysplasia and dysmorphology or long-term 
ventilator dependency were the next highest yield (group 
4 and 5). Children with infection, sepsis and immune or 
respiratory dysfunction were the least likely to receive a 
molecular genetic diagnosis (groups 6–11).
Given that dysmorphism was a predictor of a molecu-
lar diagnosis in both NICU and PICU, we calculated 
the diagnostic yield in children who did not have docu-
mented dysmorphology. In NICU the yield was 9% com-
pared to 13% overall and in PICU 18% compared to 25%.
We then compared the phenotypes of the diagnosed 
probands with the known phenotypes reported to be 
associated with the identified disease-causing genes. To 
do this, we calculated the HPO term profile similarity 
score between each proband and every published gene 
in OMIM (Online Mendelian Inheritance in Man, www.
omim.org) that has been annotated with HPO terms. 
Only in 10% of cases did the phenotype of the child pre-
dict accurately the most likely gene to cause disease. For 
the remaining 90% of cases the gene that caused disease 
could not be easily predicted (Fig.  3). In one case, the 
diagnosed gene (NDUFA6) was so recently published 
that it was not yet  included in the OMIM-to-HPO 
build [24]. Importantly, more extensive phenotyping 
in the proband did not correlate with improved simi-
larity ranking of the gene (Supp. Fig. 8a) and there was 
no difference in the number of HPO terms per proband 
between the diagnosed and non-diagnosed sets (Supp. 
Fig. 9). However, the number of HPO terms associated 
with a specific gene can improve specificity. Genes with 
a large number of phenotypes previously reported to be 
associated with the gene tend to rank higher, although 
for some genes an unusual combination of only a few 
HPO terms was sufficient to rank highly (Supp. Fig. 8b).
Table 2 Probands grouped by phenotype similarity
a Phenotypes significantly enriched in group over cohort from ward (Fisher’s exact test, FDR < 0.1) and found in at least half of the probands in the group. Simplified 
for ontology redundancy. For rows representing multiple groups, the most descriptive terms are listed for each
b Most enriched term in a group with no significantly enriched terms
c Gene only partially explains phenotype
Ward Group(s) Diagnostic rate Number of probands Enriched  phenotypesa Diagnosed genes
NICU 1 100% 2 Hypertelorism, Talipes COL2A1, FLNB
2 50% 4 None significant. Top  hitsb: Abnormal renal physiol‑
ogy, Abnormal urine output
CYP21A2, NPHS2
3 50% 2 Abnormal heart valve morphology KAT6B
4 33% 3 Cleft palate, Micrognathia 16 Mb deletion
5–10 10–25% (avg. 17%) 4–15 (avg. 8) 5: Abnormal vascular  physiologyb; 6: Abnormal mor‑
phology of the great  vesselsb; 7: Abnormality of 
the nervous system; 8: Tachypnoea; 9: Decreased 
body weight; 10: Sepsis
TTN; CHD7, NIPBL, 24 Mb dele‑
tion; DNAH11; MAP2K1; MTM1; 
SATB2
11–15 0% 4–14 (avg. 9) 11: Abnormality of nervous system physiology (HIE); 
12:  Hyperglycaemiab; 13: Abnormality of the amni‑
otic fluid; 14: Meconium‑stained amniotic fluid; 15: 
Ventriculomegaly
–
PICU 1 50% 4 None significant. Top  hitb: Abnormality of the 
amniotic fluid
BRAF, RHOBTB2
2 50% 2 None significant. Top  hitb: Lactic acidosis NDUFA6
3 40% 5 Cerebral palsy SCN2A, COL2A1c
4 36% 11 Abnormality of body height, Abnormality of skull 
size, Short stature
SMC1A, ARID1B, PPP2R5D, HBBc
5 33% 3 Ventilator dependence with inability to wean PYGM
6–8 13–25% (avg. 20%) 4–15 (avg. 9) 6: Congenital malformation of the great arteries; 7: 
Feeding  difficultiesb;
8: Abnormality of immune system physiology, 
Sepsis, Respiratory tract infection
TGFBR1; ASXL3, ARID1B; DMD, GK
9–11 0% 2–4 (avg. 3) 9: Functional respiratory  abnormalityb; 10: Joint 
hypermobility; 11: Prolonged neonatal jaundice
–
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Discussion
Whole genome sequence analysis is increasingly being 
used to diagnose rare diseases in order  to stratify 
patients for anti-seizure control, cancer treatments and 
clinical trials including gene therapy [26, 27]. Because 
the genome encodes information relevant to both acute 
and distant health risks, maximum benefit could be 
achieved by applying this technique early in life. Whilst 
the use of WGS in newborn screening is still under dis-
cussion, there is broad consensus that WGS has the 
potential to improve acute treatment of seriously ill 
babies [28].
WGS shows that underlying genetic conditions are 
prevalent in approximately 20% of intensively ill neonates 
and children selected for testing
We have created a timely-turnaround WGS trio analy-
sis process for diagnosing severely ill children within 
the NHS infrastructure for clinical practice implemen-
tation. The study sought to identify a genetic cause of 
disease in children admitted to PICU and NICU and the 
recruitment criteria required there to be phenotypic fea-
tures predicting a rare genetic cause of disease and did 
not include all admissions. The selection of this cohort is 
therefore likely to be enriched for a diagnosis and would 
be lower if all admissions were tested. The opportunity 
for WGS analysis was well received in the NICU and 
PICU by staff and parents. Parental motivations for con-
senting to the study included finding a cause for their 
child’s illness, the ability to potentially rule out a genetic 
condition, and an altruistic component to support 
improvement in healthcare for families in similar circum-
stances. Nevertheless, half of families who were eligible 
declined or did not respond to the offer of recruitment. 
Reasons given by families when declining participa-
tion can be broadly categorised as not being ready for 
a genetic diagnosis in the neonatal period, being too 
overwhelmed during the child’s critical illness, believing 
their child’s symptoms were not due to a genetic cause, 
or concerns over a genetic ‘label’. We noted that tim-
ing and appropriateness of the approach were crucial to 
full and informed consent and required a dedicated and 
trained person. Future studies are needed to focus on fur-
ther understanding family perceptions surrounding these 
issues and ascertainment bias of the consented cohort.
Diagnosis has clinical utility
The ability to find a diagnosis in a timely manner for 
neonates and children was well received by profession-
als caring for these children. The availability of a result 
to inform discussions with families around palliative care 
was welcomed where a genetic diagnosis was associated 
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with a known and poor prognosis. For some cases, early 
diagnosis allowed for interventions such as gene/disor-
der-specific medications (e.g. for epilepsy) and for sur-
veillance and monitoring that can reduce harm in the 
long term (Fig. 2). A molecular diagnosis can obviate the 
need for muscle biopsy for mitochondrial and muscle 
diseases or further MRI scanning. For parents, a diagno-
sis and the removing of uncertainty for the family were 
valued; however, where the diagnosis was associated with 
a poor prognosis, it brought grief and loss. For 14 fami-
lies the diagnosis gave reproductive choice not previously 
available (Fig. 2) and a number of couples had subsequent 
unaffected pregnancies.
Evidence that WGS should be offered to NICU/PICU 
patients
Whilst there were some phenotypic groups with 
increased likelihood of a genetic diagnosis (e.g. dysmor-
phology, neurological features), restricting recruitment 
to these specific phenotypes would have missed many 
important diagnoses. We found that the genotype is 
sufficient to drive the diagnosis with phenotypes assist-
ing with variant interpretation rather than gene selec-
tion, especially since de novo pathogenic mutations were 
common (68%) in this cohort. In-depth phenotyping is 
critical when interrogating multiple different potentially 
pathogenic variants (common for singleton cases). How-
ever, we observed that even extensive phenotyping did 
not always strongly imply a particular gene or genes, indi-
cating that predicting the disease gene based on pheno-
type will often be inaccurate. In neonates and infants, it is 
difficult to distinguish between transient and constitutive 
symptoms. Thus, the ability to perform a comprehensive 
gene agnostic trio analysis with WGS on 90% of our sam-
ples was advantageous over any single gene or panel tests 
as it did not require a phenotype-based hypothesis. Addi-
tionally, a negative result was more informative as almost 
all known disease-causing genes were assessed, signifi-
cantly decreasing the likelihood of a genetic cause. In a 
cohort of intensively ill neonates and young children, our 
findings support the use of gene agnostic trio WGS for 
cases where a single gene disorder is suspected.
Advantages of a WGS pipeline and caveats
Trio WGS analysis has many advantages over singleton 
whole exome sequencing (WES) including improved 
copy number calling, mitochondrial and inter-genetic 
mutations, and increased analysis speed and robustness, 
but it does carry a higher up-front cost. We note that 
30× WGS (and WES) short read analysis lacks the capac-
ity to identify all known diagnostic regions of the genome 
routinely needed in neonatal care such as repetitive 
sequences, homologous genes, and epigenetic modifica-
tions. These include homozygous exon 7 and 8 deletions 
in SMN1 causing spinal muscular atrophy type 1 (one 
case in this cohort) and methylation defects (two cases in 
this cohort: Kagami–Ogata and Beckwith–Wiedemann 
syndrome). In addition, very low levels of mosaicism in 
the child will not be reliably detected.
Variants of uncertain significance (VUS) and additional 
findings were not reported to families as per first tier 
consent, which included only the resolution of diagnos-
tic uncertainty. This cautious approach to data feedback 
was adopted because the use of systematic WGS in the 
neonatal setting in the UK is novel [28]. However, there 
is still uncertainty regarding the interpretation of some 
variants due to the paucity of reports of congenital pres-
entations of these disorders. This can render the WGS 
data analysis complex because of the blurred boundaries 
between diagnostic and predictive findings. Although by 
default we did not include autosomal dominant inherited 
variants in order to avoid identifying additional findings, 
some diseases with variable penetrance or expressiv-
ity have incidence in the childhood period. To mitigate 
this, variants in specific genes were examined on request 
when suspected by clinicians, though no such findings 
have been made to date.
An enduring research database resource
All families were additionally consented to the NIHR 
BioResource, permitting ongoing research with the data. 
Establishing this as a research platform enabled iterative 
re-evaluation of phenotypes and genotypes over time and 
the continuing influence on care of patients and families. 
WGS allows for discovery of novel disease-causing ele-
ments, including genes and regulatory elements [18, 29]. 
Re-analysis of WGS with improved variant calling and 
new gene discovery can substantially increase the diag-
nostic yield [30]. Indeed, in this cohort, three of the diag-
noses were for genes first published since August 2017, 
including one case that contributed to the reporting of 
a novel mitochondrial disorder [24]. Improvements to 
genomic analysis pipelines are ongoing, such as assess-
ing the analytical validity of an algorithm developed to 
detect abnormalities associated with expansion disorders 
relevant to the neonatal period (ExpansionHunter) [31].
Conclusion
In summary, this study shows that rapid whole genome 
sequencing for diagnostic purposes is feasible at scale 
within the existing infrastructure of the NHS. WGS anal-
ysis of trios in NICU and PICU identified the underly-
ing cause of disease in 13–25% of individuals who were 
selected for testing. A genotype-driven approach ensured 
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that all genes were considered equally as the phenotype 
of the child in PICU and NICU was a poor predictor of 
the specific gene identified. Finally, our findings suggest 
that WGS in neonatal and paediatric intensive care pro-
vides a unique opportunity to build a research resource 
of children with early detection of genetic diseases, 
which are eligible for clinical trials of rare diseases at a 
potentially more therapeutically responsive stage in the 
disease. Adoption of these procedures could alter acute 
management and life course outcomes for children with 
chronic diseases using stratified therapeutics.
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